Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for Chronic Pain in hEDS
NCT05405257Phase 2Terminated
- Sponsor
- Baylor College of Medicine
- Start
- May 2022
- Primary completion
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of oxytocin in hypermobile Ehlers-Danlos syndrome (hEDS), sponsored by Baylor College of Medicine. Started May 2022; status: terminated.
02
Drugs
oxytocin
03
Conditions
hypermobile Ehlers-Danlos syndrome (hEDS)
Beyond the preview
Go deeper on NCT05405257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05405257.